首页 > 最新文献

JNCI Cancer Spectrum最新文献

英文 中文
Trends in age and prostate-specific antigen at prostate cancer diagnosis between 2010 and 2019. 2010 年至 2019 年诊断前列腺癌时的年龄和前列腺特异性抗原趋势。
IF 3.4 Q2 ONCOLOGY Pub Date : 2024-11-01 DOI: 10.1093/jncics/pkae106
Lukas Owens, Ojas Brahme, Roman Gulati, Ruth Etzioni

Recent studies have shown that de novo metastatic prostate cancer incidence in the United States increased from 2010 to 2019. Plausible explanations include delayed detection after recommendations against prostate cancer screening or upstaging associated with use of more sensitive imaging technologies. Using Surveillance, Epidemiology, and End Results patient cases and controlling for aging of the population, we found the median age and prostate-specific antigen (PSA) level at prostate cancer diagnosis increased by 1.4 years of age (95% CI = 1.3 to 1.5 years) and 1.4 ng/mL (95% CI = 1.4 to 1.5 ng/mL) over this period, consistent with the delayed detection hypothesis. Racial differences were noted, with 75th percentiles of PSA at diagnosis increasing by 4.3 ng/mL (95% CI = 3.7 to 4.8 ng/mL) over this time period for non-Hispanic Black men compared with 3.0 ng/mL (95% CI = 2.8 to 3.2 ng/mL) for non-Hispanic White men. Overall, patient characteristics at diagnosis suggest that delayed detection contributed at least in part to increases in de novo metastatic disease.

最近的研究表明,美国新发转移性前列腺癌的发病率在 2010 年至 2019 年期间有所上升。合理的解释包括:建议不要进行前列腺癌筛查后,发现时间推迟;或使用更敏感的成像技术后,发现时间提前。利用监测、流行病学和最终结果病例并控制人口老龄化,我们发现在此期间,前列腺癌诊断时的中位年龄和前列腺特异性抗原(PSA)水平分别增加了 1.4 岁(95% CI 1.3-1.5)和 1.4 纳克/毫升(95% CI 1.4-1.5),与延迟检测假说一致。在这一时期,非西班牙裔黑人男性诊断时 PSA 的第 75 百分位数增加了 4.3 纳克/毫升(95% CI 3.7-4.8),而非西班牙裔白人男性则为 3.0 纳克/毫升(95% CI 2.8-3.2)。总体而言,诊断时的患者特征表明,延迟检测至少在一定程度上导致了新发转移性疾病的增加。
{"title":"Trends in age and prostate-specific antigen at prostate cancer diagnosis between 2010 and 2019.","authors":"Lukas Owens, Ojas Brahme, Roman Gulati, Ruth Etzioni","doi":"10.1093/jncics/pkae106","DOIUrl":"10.1093/jncics/pkae106","url":null,"abstract":"<p><p>Recent studies have shown that de novo metastatic prostate cancer incidence in the United States increased from 2010 to 2019. Plausible explanations include delayed detection after recommendations against prostate cancer screening or upstaging associated with use of more sensitive imaging technologies. Using Surveillance, Epidemiology, and End Results patient cases and controlling for aging of the population, we found the median age and prostate-specific antigen (PSA) level at prostate cancer diagnosis increased by 1.4 years of age (95% CI = 1.3 to 1.5 years) and 1.4 ng/mL (95% CI = 1.4 to 1.5 ng/mL) over this period, consistent with the delayed detection hypothesis. Racial differences were noted, with 75th percentiles of PSA at diagnosis increasing by 4.3 ng/mL (95% CI = 3.7 to 4.8 ng/mL) over this time period for non-Hispanic Black men compared with 3.0 ng/mL (95% CI = 2.8 to 3.2 ng/mL) for non-Hispanic White men. Overall, patient characteristics at diagnosis suggest that delayed detection contributed at least in part to increases in de novo metastatic disease.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11578289/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142500639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rural-urban disparities and trends in cancer screening: an analysis of Behavioral Risk Factor Surveillance System data (2018-2022). 癌症筛查中的城乡差异与趋势:行为风险因素监测系统数据分析(2018-2022 年)》。
IF 3.4 Q2 ONCOLOGY Pub Date : 2024-11-01 DOI: 10.1093/jncics/pkae113
Gabriel A Benavidez, Ami E Sedani, Tisha M Felder, Matthew Asare, Charles R Rogers

Background: Despite evidence of the benefit of routine cancer screenings, data show a concerning decline in cancer screening uptake for multiple cancers. This analysis aimed to examine rural-urban differences in recent trends for being up-to-date with screenings for breast, cervical, and colorectal cancers.

Methods: We used 2018, 2020, and 2022 Behavioral Risk Factor Surveillance System data to assess up-to-date cancer screening status among eligible adults in the United States. We calculated weighted prevalence estimates overall and stratified by county-level rural-urban classification. We used survey-weighted multivariable logistic regression models to examine rural-urban disparities in cancer screening up-to-date status by year.

Results: Prevalence of being up-to-date with each cancer screening was lower in 2022 than it was in 2018. The largest decline in screening overall was for cervical cancer, which dropped from 81.89% in 2018 to 47.71% in 2022. Rural-urban disparities were observed for breast cancer screening from 2018 to 2022, with the odds of up-to-date screening being 14% to 27% lower for rural populations than for urban populations. For colorectal and cervical cancers, the odds of being up-to-date with screenings were lower for rural populations in 2018 and 2020, but no statistically significant difference was observed in 2022 (colorectal screening odds ratio = 0.96, 95% CI = 0.90 to 1.02; cervical screening odds ratio = 0.97, 95% CI = 0.93 to 1.03).

Conclusion: There is a concerning trend of decreasing uptake of cancer screenings that will challenge future efforts in cancer prevention and control. There is a need to better understand the factors contributing to the decline in cancer screening update.

背景:尽管有证据表明常规癌症筛查有益,但数据显示多种癌症筛查的接受率下降令人担忧。这项分析旨在研究城乡居民在接受乳腺癌、宫颈癌和结直肠癌筛查方面的最新趋势差异:我们使用 2018 年、2020 年和 2022 年行为风险因素监测系统数据来评估符合条件的美国成年人的最新癌症筛查状况。我们计算了总体加权患病率估计值,并按县级城乡分类进行了分层。我们使用调查加权多变量逻辑回归模型来研究各年癌症筛查最新状态的城乡差异:2022年各项癌症筛查的最新筛查率均低于2018年。宫颈癌筛查总体下降幅度最大,从 2018 年的 81.89% 降至 2022 年的 47.71%。从 2018 年到 2022 年,在乳腺癌筛查方面观察到了城乡差异,农村人口的最新筛查几率比城市人口低 14% 到 27%。在结直肠癌和宫颈癌筛查方面,2018 年和 2020 年农村人口的最新筛查几率较低,但 2022 年没有观察到显著差异(结直肠癌筛查 OR = 0.96;95% CI:0.90,1.02)(宫颈癌筛查 OR = 0.97;95% CI:0.93,1.03):癌症筛查率下降的趋势令人担忧,这将对未来的癌症预防和控制工作提出挑战。需要努力更好地了解导致癌症筛查率下降的因素。
{"title":"Rural-urban disparities and trends in cancer screening: an analysis of Behavioral Risk Factor Surveillance System data (2018-2022).","authors":"Gabriel A Benavidez, Ami E Sedani, Tisha M Felder, Matthew Asare, Charles R Rogers","doi":"10.1093/jncics/pkae113","DOIUrl":"10.1093/jncics/pkae113","url":null,"abstract":"<p><strong>Background: </strong>Despite evidence of the benefit of routine cancer screenings, data show a concerning decline in cancer screening uptake for multiple cancers. This analysis aimed to examine rural-urban differences in recent trends for being up-to-date with screenings for breast, cervical, and colorectal cancers.</p><p><strong>Methods: </strong>We used 2018, 2020, and 2022 Behavioral Risk Factor Surveillance System data to assess up-to-date cancer screening status among eligible adults in the United States. We calculated weighted prevalence estimates overall and stratified by county-level rural-urban classification. We used survey-weighted multivariable logistic regression models to examine rural-urban disparities in cancer screening up-to-date status by year.</p><p><strong>Results: </strong>Prevalence of being up-to-date with each cancer screening was lower in 2022 than it was in 2018. The largest decline in screening overall was for cervical cancer, which dropped from 81.89% in 2018 to 47.71% in 2022. Rural-urban disparities were observed for breast cancer screening from 2018 to 2022, with the odds of up-to-date screening being 14% to 27% lower for rural populations than for urban populations. For colorectal and cervical cancers, the odds of being up-to-date with screenings were lower for rural populations in 2018 and 2020, but no statistically significant difference was observed in 2022 (colorectal screening odds ratio = 0.96, 95% CI = 0.90 to 1.02; cervical screening odds ratio = 0.97, 95% CI = 0.93 to 1.03).</p><p><strong>Conclusion: </strong>There is a concerning trend of decreasing uptake of cancer screenings that will challenge future efforts in cancer prevention and control. There is a need to better understand the factors contributing to the decline in cancer screening update.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11671142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142620722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systematic review of associations between anxiety, depression, and functional/biological aging among cancer survivors. 癌症幸存者焦虑、抑郁和功能/生物衰老之间关系的系统性回顾。
IF 3.4 Q2 ONCOLOGY Pub Date : 2024-11-01 DOI: 10.1093/jncics/pkae100
Brennan Parmelee Streck, Dilorom Sass, Rachelle Brick, Leah Fisk, Alicia A Livinski, Jennifer L Guida

Background: Evidence suggests a mind-body component to aging through which psychological distress from anxiety and depression drives molecular changes that promote early decline (ie, accelerated aging). Cancer survivors experience particularly high rates of anxiety and depression. Some survivors also have accelerated aging, though the relationships between anxiety and depression and aging are not clear. A synthesis of evidence is needed to understand the state of the science and impending priorities.

Methods: PubMed, Embase, CINAHL, Web of Science, and PsycNet databases were searched for studies that measured associations between depression, anxiety, and nonchronological aging in cancer survivors (2012-2022). Data were methodologically evaluated.

Results: Survivorship studies were included if they were peer reviewed, published in English from 2012 to 2022, and measured associations between anxiety and depression and aging. In total, 51 studies were included. Just over half were cross-sectional (53%). Foci included functional (n = 35 [69%]) and biological (n = 16 [31%]). Functional aging measures included frailty, sarcopenia, geriatric assessment, and cognition. Biological aging measures included telomere length, telomerase, age-related inflammatory blood-based biomarkers, renal insufficiency, anemia, and DNA methylation. We tested 223 associations. Associations between anxiety, depression, and aging were generally positive, though with varying strengths. Most compelling were associations between functional aging and depression. There were concerns for selection and measurement biases.

Conclusions: Findings suggest positive associations between anxiety, depression, and aging among cancer survivors. Future work is needed to clarify temporality, develop a consensus on the measurement of aging, and diversify cohorts.

背景:有证据表明,衰老是由身心因素引起的,焦虑和抑郁所造成的心理困扰会促使分子发生变化,从而促进早衰(即加速衰老)。癌症幸存者的焦虑和抑郁率特别高。尽管焦虑/抑郁与衰老之间的关系尚不明确,但一些幸存者也会加速衰老。需要对证据进行综合分析,以了解科学现状和即将出现的优先事项:方法:在 PubMed、Embase、CINAHL、Web of Science 和 PsycNet 数据库中搜索了癌症幸存者抑郁、焦虑和非时间性衰老之间关系的研究(2012 年至 2022 年)。对数据进行了方法学评估:纳入的幸存者研究必须经过同行评议、在 2012 年至 2022 年期间以英文发表、并测量了焦虑/抑郁与衰老之间的关联。共纳入 51 项研究。一半以上为横断面研究(53%)。研究重点包括功能性(35 项,占 69%)和生物性(16 项,占 31%)。功能性老化测量包括虚弱、肌肉疏松症、老年评估和认知。生物老化指标包括端粒长度、端粒酶、与年龄相关的炎症性血液生物标志物、肾功能不全、贫血和 DNA 甲基化。共测试了 223 项关联。焦虑、抑郁和衰老之间的关联总体上呈正相关,但强度不一。最有说服力的是功能性衰老与抑郁之间的关联。结论:研究结果表明,癌症幸存者的焦虑、抑郁和衰老之间存在正相关。今后的工作需要明确时间性,就衰老的操作方法达成共识,并使群组多样化。
{"title":"Systematic review of associations between anxiety, depression, and functional/biological aging among cancer survivors.","authors":"Brennan Parmelee Streck, Dilorom Sass, Rachelle Brick, Leah Fisk, Alicia A Livinski, Jennifer L Guida","doi":"10.1093/jncics/pkae100","DOIUrl":"10.1093/jncics/pkae100","url":null,"abstract":"<p><strong>Background: </strong>Evidence suggests a mind-body component to aging through which psychological distress from anxiety and depression drives molecular changes that promote early decline (ie, accelerated aging). Cancer survivors experience particularly high rates of anxiety and depression. Some survivors also have accelerated aging, though the relationships between anxiety and depression and aging are not clear. A synthesis of evidence is needed to understand the state of the science and impending priorities.</p><p><strong>Methods: </strong>PubMed, Embase, CINAHL, Web of Science, and PsycNet databases were searched for studies that measured associations between depression, anxiety, and nonchronological aging in cancer survivors (2012-2022). Data were methodologically evaluated.</p><p><strong>Results: </strong>Survivorship studies were included if they were peer reviewed, published in English from 2012 to 2022, and measured associations between anxiety and depression and aging. In total, 51 studies were included. Just over half were cross-sectional (53%). Foci included functional (n = 35 [69%]) and biological (n = 16 [31%]). Functional aging measures included frailty, sarcopenia, geriatric assessment, and cognition. Biological aging measures included telomere length, telomerase, age-related inflammatory blood-based biomarkers, renal insufficiency, anemia, and DNA methylation. We tested 223 associations. Associations between anxiety, depression, and aging were generally positive, though with varying strengths. Most compelling were associations between functional aging and depression. There were concerns for selection and measurement biases.</p><p><strong>Conclusions: </strong>Findings suggest positive associations between anxiety, depression, and aging among cancer survivors. Future work is needed to clarify temporality, develop a consensus on the measurement of aging, and diversify cohorts.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11631420/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142500638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Posttreatment surveillance intensity and overall survival in prostate cancer survivors (AFT-30). 前列腺癌幸存者的治疗后监测强度和总生存率(AFT-30)。
IF 4.3 Q2 ONCOLOGY Pub Date : 2024-11-01 DOI: 10.1093/jncics/pkae099
Ronald C Chen, Ramsankar Basak, Stacie Dusetzina, Deborah S Usinger, Zahed Mohammed, Aaron D Falchook, Jessica R Schumacher, Amanda B Francescatti, Amanda Cuddy, George J Chang, Benjamin D Kozower, Caprice C Greenberg, Anne K Barber, Aaron J Katz

Background: Posttreatment surveillance affects millions of cancer survivors, but empiric data to guide clinical practice are lacking. This study assessed whether the intensity of surveillance testing after radical prostatectomy or radiation therapy for localized prostate cancer is associated with overall survival.

Methods: Men diagnosed with localized prostate cancer between 2005 and 2010 who underwent radical prostatectomy or radiation therapy at a Commission on Cancer-accredited facility were randomly sampled. Primary data collected from 10 147 patients sampled across 1007 facilities were linked with existing data from the National Cancer Database. Analysis examined whether intensity of surveillance measured as the number of prostate-specific antigen (PSA) tests in the first year after primary treatment (categorized as 0-1 [low intensity], 2 [medium], or ≥3 [high intensity] PSA tests) was associated with overall survival. Secondary outcomes included recurrence-free survival (RFS) and subsequent use of imaging tests, biopsy procedures, and salvage treatment.

Results: Median follow-up exceeded 8 years from prostate cancer diagnosis. Overall survival was not statistically significantly different across surveillance intensity groups among radiation therapy (P = .59) or radical prostatectomy (P = .29) patients. RFS was not statistically significantly different across surveillance intensity groups for radiation therapy (P = .13) patients but was for radical prostatectomy (P = .01) patients with high intensity associated with the worst RFS. In both treatments, higher surveillance intensity was associated with more procedures and salvage treatments.

Conclusions: In patients with localized prostate cancer, more frequent PSA surveillance testing after radical prostatectomy or radiation therapy was associated with increased procedures and salvage treatments but not overall survival.

背景:治疗后监测影响着数百万癌症幸存者,但缺乏经验数据来指导临床实践。本研究评估了局部前列腺癌根治性前列腺切除术(RP)或放射治疗(RT)后监测检测的强度是否与总生存率有关:方法:随机抽样 2005 年至 2010 年期间确诊为局部前列腺癌并在癌症委员会认可的医疗机构接受前列腺癌根治术或放疗的男性患者。从 1007 家医疗机构的 10147 名患者中收集的原始数据与国家癌症数据库中的现有数据进行了关联。分析检验了以初级治疗后第一年的 PSA 检测次数(分为 0-1 次(低强度)、2 次(中强度)或≥ 3 次(高强度)PSA 检测)来衡量的监测强度是否与总生存率相关。次要结果包括无复发生存率(RFS)以及随后使用的成像检测、活检程序和挽救治疗:结果:自前列腺癌确诊起,中位随访时间超过 8 年。RT(P = .59)或RP(P = .29)患者的OS在不同监测强度组间无明显统计学差异。RT(P = .13)患者的 RFS 在不同监控强度组间无明显统计学差异,但 RP(P = .01)患者的 RFS 与高监控强度相关,RFS 较差。在两种治疗方法中,较高的监控强度与较多的手术和挽救治疗有关:结论:在局部前列腺癌患者中,根治性前列腺切除术或放射治疗后更频繁地进行 PSA 监测与手术和挽救治疗的增加有关,但与总生存率无关。
{"title":"Posttreatment surveillance intensity and overall survival in prostate cancer survivors (AFT-30).","authors":"Ronald C Chen, Ramsankar Basak, Stacie Dusetzina, Deborah S Usinger, Zahed Mohammed, Aaron D Falchook, Jessica R Schumacher, Amanda B Francescatti, Amanda Cuddy, George J Chang, Benjamin D Kozower, Caprice C Greenberg, Anne K Barber, Aaron J Katz","doi":"10.1093/jncics/pkae099","DOIUrl":"10.1093/jncics/pkae099","url":null,"abstract":"<p><strong>Background: </strong>Posttreatment surveillance affects millions of cancer survivors, but empiric data to guide clinical practice are lacking. This study assessed whether the intensity of surveillance testing after radical prostatectomy or radiation therapy for localized prostate cancer is associated with overall survival.</p><p><strong>Methods: </strong>Men diagnosed with localized prostate cancer between 2005 and 2010 who underwent radical prostatectomy or radiation therapy at a Commission on Cancer-accredited facility were randomly sampled. Primary data collected from 10 147 patients sampled across 1007 facilities were linked with existing data from the National Cancer Database. Analysis examined whether intensity of surveillance measured as the number of prostate-specific antigen (PSA) tests in the first year after primary treatment (categorized as 0-1 [low intensity], 2 [medium], or ≥3 [high intensity] PSA tests) was associated with overall survival. Secondary outcomes included recurrence-free survival (RFS) and subsequent use of imaging tests, biopsy procedures, and salvage treatment.</p><p><strong>Results: </strong>Median follow-up exceeded 8 years from prostate cancer diagnosis. Overall survival was not statistically significantly different across surveillance intensity groups among radiation therapy (P = .59) or radical prostatectomy (P = .29) patients. RFS was not statistically significantly different across surveillance intensity groups for radiation therapy (P = .13) patients but was for radical prostatectomy (P = .01) patients with high intensity associated with the worst RFS. In both treatments, higher surveillance intensity was associated with more procedures and salvage treatments.</p><p><strong>Conclusions: </strong>In patients with localized prostate cancer, more frequent PSA surveillance testing after radical prostatectomy or radiation therapy was associated with increased procedures and salvage treatments but not overall survival.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142390604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of chemotherapy on patients with mismatch repair deficient advanced endometrial carcinomas-a meta-analysis. 化疗对错配修复缺陷晚期子宫内膜癌患者的影响--一项荟萃分析。
IF 3.4 Q2 ONCOLOGY Pub Date : 2024-11-01 DOI: 10.1093/jncics/pkae101
Angelina Tjokrowidjaja, Peey-Sei Kok, Yoland C Antill, Clare L Scott, Linda R Mileshkin, Michael L Friedlander, Chee K Lee

Background: Chemo-immunotherapy is standard of care for women with recurrent or advanced mismatch repair deficient endometrial carcinoma. However, it is uncertain whether patients with mismatch repair deficient advanced or recurrent endometrial carcinoma derive less benefit from chemotherapy than those with mismatch repair proficient endometrial carcinoma.

Methods: We performed a meta-analysis of randomized controlled trials (RCTs) in advanced or recurrent endometrial carcinoma to determine the difference in the benefit of chemotherapy in mismatch repair deficient vs mismatch repair proficient endometrial carcinoma. Data on chemotherapy outcomes including objective response rate, progression-free survival (PFS), and overall survival were retrieved. We pooled these data using the inverse variance method and examined subgroup difference by mismatch repair status. We also compared differences in PFS and overall survival outcomes by creating individual patient data from the Kaplan-Meier curves of trial publications for sensitivity analyses.

Results: A total of 5 RCTs with 1137 participants (mismatch repair deficient, 26%; mismatch repair proficient, 74%) were included. All participants were treated with carboplatin-based chemotherapy. There was no difference between the mismatch repair deficient and mismatch repair proficient subgroups for objective response rate (66.5% vs 64.0%; P = .20 for subgroup difference), PFS (hazard ratio [HR] = 0.93, 95% confidence interval [CI] = 0.77 to 1.12; P = .44; median PFS = 7.6 vs 9.5 months) or overall survival (HR = 1.03, 95% CI = 0.73 to 1.44; P = .88; median overall survival = not reached vs 28.6 months).

Conclusions: Objective response rate, PFS, and overall survival were similar among those with mismatch repair deficient vs mismatch repair proficient endometrial cancer treated with front-line, platinum-doublet chemotherapy in RCTs. These findings reinforce the importance of combining chemotherapy together with immune checkpoint inhibitors until the results of trials comparing immune checkpoint therapy alone with combination therapy are available.

简介:化疗免疫疗法是治疗复发或晚期错配修复缺陷(dMMR)子宫内膜癌(EC)妇女的标准疗法。然而,目前还不确定dMMR晚期或复发性子宫内膜癌患者从化疗中获得的益处是否少于错配修复熟练型(pMMR)子宫内膜癌患者:我们对晚期/复发性EC的随机对照试验(RCT)进行了荟萃分析,以确定dMMR与pMMR EC化疗获益的差异。我们检索了化疗结果数据,包括客观反应率(ORR)、无进展生存期(PFS)和总生存期(OS)。我们使用逆方差法汇总了这些数据,并根据 MMR 状态研究了亚组差异。我们还通过从试验出版物的 Kaplan-Meier 曲线中创建单个患者数据来比较 PFS 和 OS 结果的差异,以进行敏感性分析:共纳入了 5 项 RCT,1137 名参与者(dMMR,26%;pMMR,74%)。所有参与者均接受了以卡铂为基础的化疗。dMMR亚组和pMMR亚组在ORR(66.5% vs 64.0%,亚组差异P = .20)、PFS(HR 0.93,95% CI 0.77-1.12,P = .44;中位PFS 7.6 vs 9.5个月)或OS(HR 1.03,95% CI 0.73-1.44,P = .88;未达到中位OS vs 28.6个月)方面没有差异:结论:在随机临床试验中,dMMR与pMMR子宫内膜癌患者接受一线铂双药化疗的ORR、PFS和OS相似。这些发现加强了化疗与免疫检查点抑制剂联合治疗的重要性,直到将免疫检查点疗法单独与联合疗法进行比较的试验结果出来为止。
{"title":"Impact of chemotherapy on patients with mismatch repair deficient advanced endometrial carcinomas-a meta-analysis.","authors":"Angelina Tjokrowidjaja, Peey-Sei Kok, Yoland C Antill, Clare L Scott, Linda R Mileshkin, Michael L Friedlander, Chee K Lee","doi":"10.1093/jncics/pkae101","DOIUrl":"10.1093/jncics/pkae101","url":null,"abstract":"<p><strong>Background: </strong>Chemo-immunotherapy is standard of care for women with recurrent or advanced mismatch repair deficient endometrial carcinoma. However, it is uncertain whether patients with mismatch repair deficient advanced or recurrent endometrial carcinoma derive less benefit from chemotherapy than those with mismatch repair proficient endometrial carcinoma.</p><p><strong>Methods: </strong>We performed a meta-analysis of randomized controlled trials (RCTs) in advanced or recurrent endometrial carcinoma to determine the difference in the benefit of chemotherapy in mismatch repair deficient vs mismatch repair proficient endometrial carcinoma. Data on chemotherapy outcomes including objective response rate, progression-free survival (PFS), and overall survival were retrieved. We pooled these data using the inverse variance method and examined subgroup difference by mismatch repair status. We also compared differences in PFS and overall survival outcomes by creating individual patient data from the Kaplan-Meier curves of trial publications for sensitivity analyses.</p><p><strong>Results: </strong>A total of 5 RCTs with 1137 participants (mismatch repair deficient, 26%; mismatch repair proficient, 74%) were included. All participants were treated with carboplatin-based chemotherapy. There was no difference between the mismatch repair deficient and mismatch repair proficient subgroups for objective response rate (66.5% vs 64.0%; P = .20 for subgroup difference), PFS (hazard ratio [HR] = 0.93, 95% confidence interval [CI] = 0.77 to 1.12; P = .44; median PFS = 7.6 vs 9.5 months) or overall survival (HR = 1.03, 95% CI = 0.73 to 1.44; P = .88; median overall survival = not reached vs 28.6 months).</p><p><strong>Conclusions: </strong>Objective response rate, PFS, and overall survival were similar among those with mismatch repair deficient vs mismatch repair proficient endometrial cancer treated with front-line, platinum-doublet chemotherapy in RCTs. These findings reinforce the importance of combining chemotherapy together with immune checkpoint inhibitors until the results of trials comparing immune checkpoint therapy alone with combination therapy are available.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552623/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142465721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
County-level racial disparities in prostate cancer-specific mortality from 2005 to 2020. 2005 年至 2020 年前列腺癌特定死亡率的县级种族差异。
IF 3.4 Q2 ONCOLOGY Pub Date : 2024-11-01 DOI: 10.1093/jncics/pkae109
Samuel L Washington Iii, Mary Fakunle, Lufan Wang, Avery E Braun, Michael Leapman, Janet E Cowan, Matthew R Cooperberg

Background: Local conditions where people live continue to influence prostate cancer outcomes. By examining local characteristics associated with trends in Black-White differences in prostate cancer-specific mortality over time, we aim to identify factors driving county-level prostate cancer-specific mortality disparities over a 15-year period.

Methods: We linked county-level data (Area Health Resource File) with clinicodemographic data of men with prostate cancer (Surveillance, Epidemiology, and End Results registry) from 2005 to 2020. Generalized linear mixed models evaluated associations between race and county-level age-standardized prostate cancer-specific mortality, adjusting for age; year of death; rurality; county-level education; income; uninsured rates; and densities of urologists, radiologists, primary care practitioners, and hospital beds.

Results: In 1085 counties, 185 390 patients were identified of which 15.8% were non-Hispanic Black. Racial disparities in prostate cancer-specific mortality narrowed from 2005 to 2020 (25.4 per 100 000 to 19.2 per 100 000 overall, 57.9 per 100 000 to 38 per 100 000 for non-Hispanic Black patients, and 23.4 per 100 000 to 18.3 per 100 000 for non-Hispanic White patients). For non-Hispanic Black and non-Hispanic White patients, county prostate cancer-specific mortality changes varied greatly (-65% to +77% and -61% to +112%, respectively). From 2016 to 2020, non-Hispanic Black patients harbored greater prostate cancer-specific mortality risk (relative risk = 2.09, 95% confidence interval [CI] = 2.01 to 2.18); higher radiation oncologist density was associated with lower mortality risk (relative risk = 0.93, 95% CI = 0.89 to 0.98), while other practitioner densities were not.

Conclusion: Although overall rates improved, specific counties experienced worsening race-based disparities over time. Identifying locations of highest (and lowest) mortality disparities remains critical to development of location-specific solutions to racial disparities in prostate cancer outcomes.

背景:人们生活的当地条件继续影响着前列腺癌的治疗效果。通过研究与黑人-白人前列腺癌特异性死亡率(PCSM)随时间变化的趋势相关的地方特征,我们旨在确定在 15 年间造成县级 PCSM 差异的因素:我们将 2005 年至 2020 年的县级数据(地区卫生资源档案)与前列腺癌男性患者的门诊人口学数据(监测、流行病学和最终结果登记)联系起来。广义线性混合模型评估了种族与县级年龄标准化 PCSM 之间的关系,并调整了年龄、死亡年份、乡村、县级教育、收入、无保险率以及泌尿科医生、放射科医生、初级保健提供者和医院床位的密度:结果:确定了 1085 个县的 185,390 名患者,其中 15.8% 为非西班牙裔黑人。从 2005 年到 2020 年,PCSM 的种族差异有所缩小(总体从每 10 万人 25.4 例降至每 10 万人 19.2 例;非西班牙裔黑人患者从每 10 万人 57.9 例降至每 10 万人 38 例;非西班牙裔白人患者从每 10 万人 23.4 例降至每 10 万人 18.3 例)。对于非西班牙裔黑人和非西班牙裔白人患者而言,县级 PCSM 变化差异很大(分别为 -65% 至 + 77% 和 -61% 至 + 112%)。从2016年到2020年,非西班牙裔黑人的PCSM风险更高(RR 2.09,95% CI 2.01-2.18);放射肿瘤学家密度越高,死亡率风险越低(RR 0.93,95% CI 0.89-0.98),而其他医疗机构密度则不然:结论:尽管总体死亡率有所提高,但随着时间的推移,特定县域的种族差异在不断恶化。确定死亡率差异最高(和最低)的地区对于制定针对特定地区的前列腺癌种族差异解决方案至关重要。
{"title":"County-level racial disparities in prostate cancer-specific mortality from 2005 to 2020.","authors":"Samuel L Washington Iii, Mary Fakunle, Lufan Wang, Avery E Braun, Michael Leapman, Janet E Cowan, Matthew R Cooperberg","doi":"10.1093/jncics/pkae109","DOIUrl":"10.1093/jncics/pkae109","url":null,"abstract":"<p><strong>Background: </strong>Local conditions where people live continue to influence prostate cancer outcomes. By examining local characteristics associated with trends in Black-White differences in prostate cancer-specific mortality over time, we aim to identify factors driving county-level prostate cancer-specific mortality disparities over a 15-year period.</p><p><strong>Methods: </strong>We linked county-level data (Area Health Resource File) with clinicodemographic data of men with prostate cancer (Surveillance, Epidemiology, and End Results registry) from 2005 to 2020. Generalized linear mixed models evaluated associations between race and county-level age-standardized prostate cancer-specific mortality, adjusting for age; year of death; rurality; county-level education; income; uninsured rates; and densities of urologists, radiologists, primary care practitioners, and hospital beds.</p><p><strong>Results: </strong>In 1085 counties, 185 390 patients were identified of which 15.8% were non-Hispanic Black. Racial disparities in prostate cancer-specific mortality narrowed from 2005 to 2020 (25.4 per 100 000 to 19.2 per 100 000 overall, 57.9 per 100 000 to 38 per 100 000 for non-Hispanic Black patients, and 23.4 per 100 000 to 18.3 per 100 000 for non-Hispanic White patients). For non-Hispanic Black and non-Hispanic White patients, county prostate cancer-specific mortality changes varied greatly (-65% to +77% and -61% to +112%, respectively). From 2016 to 2020, non-Hispanic Black patients harbored greater prostate cancer-specific mortality risk (relative risk = 2.09, 95% confidence interval [CI] = 2.01 to 2.18); higher radiation oncologist density was associated with lower mortality risk (relative risk = 0.93, 95% CI = 0.89 to 0.98), while other practitioner densities were not.</p><p><strong>Conclusion: </strong>Although overall rates improved, specific counties experienced worsening race-based disparities over time. Identifying locations of highest (and lowest) mortality disparities remains critical to development of location-specific solutions to racial disparities in prostate cancer outcomes.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11631307/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Randomized pilot trial of an unconditional cash transfer intervention to address food insecurity in oncology. 无条件现金转移干预的随机试点试验,以解决肿瘤患者的粮食不安全问题。
IF 3.4 Q2 ONCOLOGY Pub Date : 2024-11-01 DOI: 10.1093/jncics/pkae107
Jean A McDougall, Shoshana Adler Jaffe, Kendal Jacobson, Tori L Shaver, Jennifer L F Wilson, Katrina Baca, Tawny Boyce, Bernard Tawfik, Janet Page-Reeves

Screening for food insecurity and other social determinants of health is being integrated into oncology practice. We performed a pilot randomized trial to investigate whether an unconditional cash transfer (UCT) could be used to address food insecurity among female breast and gynecological cancer survivors. Food-insecure cancer survivors completed a baseline survey and were randomly assigned to receive $100/month for 3 months (UCT) or usual care (UC). Participants (n = 14) completed a follow-up survey after 3 months, and we compared changes in health-related quality of life, indicators of food insecurity, diet quality, and whether a participant had to forgo, delay, or make changes to medical care because of cost. The UCT was associated with higher physical health scores, fewer indicators of food insecurity, better diet quality, and a lower likelihood of forgoing medical care than those who received UC. Our results suggest that UCTs can improve outcomes for food-insecure cancer survivors.

食品不安全及其他健康社会决定因素的筛查正被纳入肿瘤治疗实践中。我们进行了一项试点随机试验,研究是否可以使用无条件现金转移(UCT)来解决女性乳腺癌和妇科癌症幸存者的食物不安全问题。食物无保障的癌症幸存者完成了一项基线调查,并被随机分配到每月 100 美元、为期 3 个月(UCT)或常规护理(UC)中。参与者(n = 14)在 3 个月后完成了后续调查,我们比较了他们在健康相关生活质量、食物不安全指标、饮食质量以及是否因费用而放弃、推迟或改变医疗护理等方面的变化。与接受 UC 的人相比,接受 UCT 的人身体健康得分更高,食物不安全指标更少,饮食质量更好,放弃医疗的可能性更低。我们的研究结果表明,"统一治疗方案 "可以改善食物无保障癌症幸存者的治疗效果。
{"title":"Randomized pilot trial of an unconditional cash transfer intervention to address food insecurity in oncology.","authors":"Jean A McDougall, Shoshana Adler Jaffe, Kendal Jacobson, Tori L Shaver, Jennifer L F Wilson, Katrina Baca, Tawny Boyce, Bernard Tawfik, Janet Page-Reeves","doi":"10.1093/jncics/pkae107","DOIUrl":"10.1093/jncics/pkae107","url":null,"abstract":"<p><p>Screening for food insecurity and other social determinants of health is being integrated into oncology practice. We performed a pilot randomized trial to investigate whether an unconditional cash transfer (UCT) could be used to address food insecurity among female breast and gynecological cancer survivors. Food-insecure cancer survivors completed a baseline survey and were randomly assigned to receive $100/month for 3 months (UCT) or usual care (UC). Participants (n = 14) completed a follow-up survey after 3 months, and we compared changes in health-related quality of life, indicators of food insecurity, diet quality, and whether a participant had to forgo, delay, or make changes to medical care because of cost. The UCT was associated with higher physical health scores, fewer indicators of food insecurity, better diet quality, and a lower likelihood of forgoing medical care than those who received UC. Our results suggest that UCTs can improve outcomes for food-insecure cancer survivors.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11574865/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142500626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lung cancer-a one-way ticket. 肺癌--一张单程票
IF 3.4 Q2 ONCOLOGY Pub Date : 2024-11-01 DOI: 10.1093/jncics/pkae098
Drew Moghanaki, Michelle Ann Eala, Jill Feldman, Terri Ann DiJulio, Peter Gorayski
{"title":"Lung cancer-a one-way ticket.","authors":"Drew Moghanaki, Michelle Ann Eala, Jill Feldman, Terri Ann DiJulio, Peter Gorayski","doi":"10.1093/jncics/pkae098","DOIUrl":"10.1093/jncics/pkae098","url":null,"abstract":"","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":"8 6","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540168/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142589633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neighborhood homicide rate and odds of colorectal adenoma among adult patients seeking colonoscopy. 邻里凶杀率与寻求结肠镜检查的成年患者患结直肠腺瘤的几率。
IF 3.4 Q2 ONCOLOGY Pub Date : 2024-11-01 DOI: 10.1093/jncics/pkae110
Alyshia Hamm, Evgenia Karayeva, Manoela Lima Oliveira, Nabil Kahouadji, Paul Grippo, Patricia G Wolf, Ece Mutlu, Lisa Tussing-Humphreys, Sage J Kim

Background: Chronic exposure to ambient stressors, including neighborhood crime, may have a detrimental impact on the body's stress response system with implications for colorectal carcinogenesis.

Methods: We examined associations between the mean neighborhood homicide rates from 2000 and 2018 and diagnosis of colorectal adenoma among patients at the University of Illinois Health and Hospital System in Chicago, Illinois, between 2015 and 2018.

Results: Of the 5225 patients who underwent colonoscopy and were included in the analytic dataset, 60% had colorectal adenoma. Older age, male sex, and higher body mass index (BMI) were associated with greater odds of colorectal adenoma. The neighborhood homicide rate was associated with identifying as Black and Hispanic and higher BMI. A mediation analysis showed that the neighborhood homicide rate effects on colorectal adenoma were mediated through BMI.

Conclusions: The study concluded that older age, male sex, and higher BMI increases the odds of colorectal adenoma, with neighborhood homicide rate indirectly influencing this risk through its association with BMI, particularly among Black and Hispanic individuals.

背景:长期暴露于环境应激源(包括社区犯罪)可能会对人体的应激反应系统产生不利影响,并对大肠癌的发生产生影响:长期暴露于包括邻里犯罪在内的环境应激源可能会对人体的应激反应系统产生不利影响,从而对结直肠癌的发生产生影响:我们研究了伊利诺伊州芝加哥市伊利诺伊大学健康与医院系统的患者在2015年至2018年期间,2000年至2018年社区凶杀案平均发生率与结直肠腺瘤诊断之间的关联:在接受结肠镜检查并纳入分析数据集的5225名患者中,60%患有结直肠腺瘤。年龄越大、性别为男性、体重指数(BMI)越高,患结直肠腺瘤的几率越大。邻里凶杀率与黑人和西班牙裔以及较高的体重指数有关。中介分析表明,邻里凶杀率对结直肠腺瘤的影响是通过体重指数中介的:研究结论:年龄较大、男性和较高的体重指数会显著增加患结直肠腺瘤的几率,而邻里凶杀率则会通过与体重指数的关联间接影响这一风险,尤其是在黑人和西班牙裔人群中。
{"title":"Neighborhood homicide rate and odds of colorectal adenoma among adult patients seeking colonoscopy.","authors":"Alyshia Hamm, Evgenia Karayeva, Manoela Lima Oliveira, Nabil Kahouadji, Paul Grippo, Patricia G Wolf, Ece Mutlu, Lisa Tussing-Humphreys, Sage J Kim","doi":"10.1093/jncics/pkae110","DOIUrl":"10.1093/jncics/pkae110","url":null,"abstract":"<p><strong>Background: </strong>Chronic exposure to ambient stressors, including neighborhood crime, may have a detrimental impact on the body's stress response system with implications for colorectal carcinogenesis.</p><p><strong>Methods: </strong>We examined associations between the mean neighborhood homicide rates from 2000 and 2018 and diagnosis of colorectal adenoma among patients at the University of Illinois Health and Hospital System in Chicago, Illinois, between 2015 and 2018.</p><p><strong>Results: </strong>Of the 5225 patients who underwent colonoscopy and were included in the analytic dataset, 60% had colorectal adenoma. Older age, male sex, and higher body mass index (BMI) were associated with greater odds of colorectal adenoma. The neighborhood homicide rate was associated with identifying as Black and Hispanic and higher BMI. A mediation analysis showed that the neighborhood homicide rate effects on colorectal adenoma were mediated through BMI.</p><p><strong>Conclusions: </strong>The study concluded that older age, male sex, and higher BMI increases the odds of colorectal adenoma, with neighborhood homicide rate indirectly influencing this risk through its association with BMI, particularly among Black and Hispanic individuals.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11643352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neighborhood vulnerability and associations with poor health-related quality of life among adult survivors of childhood cancer. 儿童癌症成年幸存者的邻里脆弱性及与健康相关的生活质量低下的关联。
IF 3.4 Q2 ONCOLOGY Pub Date : 2024-11-01 DOI: 10.1093/jncics/pkae088
Jaesung Choi, Madeline R Horan, Tara M Brinkman, D Kumar Srivastava, Kirsten K Ness, Gregory T Armstrong, Melissa M Hudson, I-Chan Huang

Background: Few studies have investigated the relationship between neighborhood vulnerability and health-related quality of life (HRQOL) in the childhood cancer population. This study evaluated the impact of neighborhood vulnerability on HRQOL among adult survivors of childhood cancer.

Methods: This cross-sectional study included 4393 adult survivors of childhood cancer from the St Jude Lifetime Cohort Study. At the baseline (2007-2020), HRQOL was assessed using the SF36v2's physical and mental components summaries (PCS and MCS). Neighborhood vulnerability was assessed using the overall, domain, and indicator-specific scores of the Social Vulnerability Index (SVI) and Minority Health SVI (MHSVI). Multivariable logistic regression was used to evaluate associations of neighborhood vulnerability (quartiles: Q1-Q4) with impaired HRQOL (1SD below the norm), adjusting for diagnosis, demographics, personal socioeconomic status (SES), lifestyle, and chronic health condition burden. Interactions of SVI and MHSVI with personal SES on impaired HRQOL were analyzed.

Results: Among survivors, 51.9% were male, averaging 30.3 years of age at evaluation and 21.5 years since diagnosis. Comparing neighborhoods with higher vs lower vulnerability (Q4 vs Q1), overall (odds ratio [OR] = 1.60, 95% confidence interval [CI] = 1.19 to 2.16) and domain-specific vulnerability (socioeconomic: OR = 1.59, 95% CI = 1.18 to 2.15; household composition: OR = 1.54, 95% CI = 1.16 to 2.06; housing and transportation: OR = 1.33, 95% CI = 1.00 to 1.76; medical vulnerability: OR = 1.60, 95% CI = 1.22 to 2.09) were significantly associated with impaired PCS, but not MCS. Residing in neighborhoods lacking urgent care clinics was significantly associated with impaired PCS (OR = 1.39, 95% CI = 1.08 to 1.78). Having lower vs higher personal education and living in higher vulnerability neighborhoods were associated with more impaired PCS (Pinteraction = .021).

Conclusions: Specific aspects of neighborhood vulnerability increase the risk for impaired physical HRQOL. Addressing these neighborhood factors is essential to enhance the HRQOL of survivors.

背景:很少有研究调查儿童癌症人群中邻里脆弱性与健康相关生活质量(HRQOL)之间的关系。本研究评估了邻里脆弱性对儿童癌症成年幸存者 HRQOL 的影响:这项横断面研究纳入了圣裘德终身队列研究(St Jude Lifetime Cohort Study)中的 4393 名儿童癌症成年幸存者。在基线期(2007-2020 年),HRQOL 采用 SF36v2 的身体/精神成分汇总表(PCS/MCS)进行评估。邻里脆弱性采用社会脆弱性指数(SVI)和少数民族健康 SVI(MHSVI)的总分、领域分和特定指标分进行评估。多变量逻辑回归用于评估邻里脆弱性(四分位数:Q1-Q4)与受损的 HRQOL(低于标准值 1SD)之间的关系,并对诊断、人口统计学、个人社会经济地位 (SES)、生活方式和慢性疾病负担进行调整。分析了SVI/MHSVI与个人社会经济地位对受损的HRQOL的交互作用:在幸存者中,51.9%为男性,评估时平均年龄为30.3岁,确诊后平均年龄为21.5岁。比较易感性较高与较低的社区(Q4 与 Q1),总体易感性(OR = 1.60,95%CI = 1.19-2.16)和特定领域的易感性(社会经济,OR = 1.59,95%CI = 1.19-2.16)均有所下降:OR = 1.59,95%CI = 1.18-2.15;家庭组成:OR=1.54,95%CI=1.16-2.06;住房/交通:OR=1.33,95%CI=1.00-1.76;医疗脆弱性:OR=1.60,95%CI=1.22-2.09)与 PCS 下降显著相关,但与 MCS 无关。居住在缺乏紧急护理诊所的社区与 PCS 受损有显著相关性(OR = 1.39,95%CI = 1.08-1.78)。个人教育程度较低与较高以及居住在较脆弱的社区都与PCS受损有关(P交互作用=0.021):结论:邻里脆弱性的某些方面会增加身体健康与生活质量受损的风险。解决这些邻里因素对于提高幸存者的 HRQOL 至关重要。
{"title":"Neighborhood vulnerability and associations with poor health-related quality of life among adult survivors of childhood cancer.","authors":"Jaesung Choi, Madeline R Horan, Tara M Brinkman, D Kumar Srivastava, Kirsten K Ness, Gregory T Armstrong, Melissa M Hudson, I-Chan Huang","doi":"10.1093/jncics/pkae088","DOIUrl":"10.1093/jncics/pkae088","url":null,"abstract":"<p><strong>Background: </strong>Few studies have investigated the relationship between neighborhood vulnerability and health-related quality of life (HRQOL) in the childhood cancer population. This study evaluated the impact of neighborhood vulnerability on HRQOL among adult survivors of childhood cancer.</p><p><strong>Methods: </strong>This cross-sectional study included 4393 adult survivors of childhood cancer from the St Jude Lifetime Cohort Study. At the baseline (2007-2020), HRQOL was assessed using the SF36v2's physical and mental components summaries (PCS and MCS). Neighborhood vulnerability was assessed using the overall, domain, and indicator-specific scores of the Social Vulnerability Index (SVI) and Minority Health SVI (MHSVI). Multivariable logistic regression was used to evaluate associations of neighborhood vulnerability (quartiles: Q1-Q4) with impaired HRQOL (1SD below the norm), adjusting for diagnosis, demographics, personal socioeconomic status (SES), lifestyle, and chronic health condition burden. Interactions of SVI and MHSVI with personal SES on impaired HRQOL were analyzed.</p><p><strong>Results: </strong>Among survivors, 51.9% were male, averaging 30.3 years of age at evaluation and 21.5 years since diagnosis. Comparing neighborhoods with higher vs lower vulnerability (Q4 vs Q1), overall (odds ratio [OR] = 1.60, 95% confidence interval [CI] = 1.19 to 2.16) and domain-specific vulnerability (socioeconomic: OR = 1.59, 95% CI = 1.18 to 2.15; household composition: OR = 1.54, 95% CI = 1.16 to 2.06; housing and transportation: OR = 1.33, 95% CI = 1.00 to 1.76; medical vulnerability: OR = 1.60, 95% CI = 1.22 to 2.09) were significantly associated with impaired PCS, but not MCS. Residing in neighborhoods lacking urgent care clinics was significantly associated with impaired PCS (OR = 1.39, 95% CI = 1.08 to 1.78). Having lower vs higher personal education and living in higher vulnerability neighborhoods were associated with more impaired PCS (Pinteraction = .021).</p><p><strong>Conclusions: </strong>Specific aspects of neighborhood vulnerability increase the risk for impaired physical HRQOL. Addressing these neighborhood factors is essential to enhance the HRQOL of survivors.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11549958/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142287466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JNCI Cancer Spectrum
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1